Annual Drug Patent Expirations for MAVENCLAD
Mavenclad is a drug marketed by Emd Serono Inc and is included in one NDA. It is available from one supplier. There are five patents protecting this drug.
Drug patent litigation for MAVENCLAD.
This drug has one hundred and thirty-one patent family members in thirty-five countries.
The generic ingredient in MAVENCLAD is cladribine. One supplier is listed for this compound. Additional details are available on the cladribine profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
